Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CONMED Corp Director's Dealing 2022

Mar 7, 2022

31971_dirs_2022-03-07_898735bc-2ed0-4654-a8eb-8ce17fa509fd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED Corp (CNMD)
CIK: 0000816956
Period of Report: 2022-03-03

Reporting Person: KENNEDY JOHN JED (Group Executive Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-03-03 Common Stock M 5092 $59.96 Acquired 14947 Direct
2022-03-03 Common Stock S 5092 $144.2521 Disposed 9855 Direct
2022-03-03 Common Stock M 1790 $78.76 Acquired 11645 Direct
2022-03-03 Common Stock S 1790 $144.3174 Disposed 9855 Direct
2022-03-03 Common Stock M 832 $97.69 Acquired 10687 Direct
2022-03-03 Common Stock S 832 $144.3304 Disposed 9855 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-03-03 Options To Purchase Common Stock $59.96 M 5092 Disposed 2028-03-01 Common Stock (5092) Direct
2022-03-03 Options To Purchase Common Stock $78.76 M 1790 Disposed 2029-03-01 Common Stock (1790) Direct
2022-03-03 Options To Purchase Common Stock $97.69 M 832 Disposed 2030-03-02 Common Stock (832) Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.25 to $144.36. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.26 to $144.50. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.26 to $144.40. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F4: The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.

F5: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period